TY - JOUR
T1 - The dynamic role of platelets in cancer progression and their therapeutic implications
AU - Li, Suping
AU - Lu, Zefang
AU - Wu, Suying
AU - Chu, Tianjiao
AU - Li, Bozhao
AU - Qi, Feilong
AU - Zhao, Yuliang
AU - Nie, Guangjun
N1 - Funding Information:
The authors want to express special thanks to T. Zhou, Westlake University, for providing helpful suggestions for our draft revision. This work was supported by grants from the Beijing Distinguished Young Scientist programme (JQ20037 to S.L.), CAS Interdisciplinary Innovation Team (JCTD-2020-04 to S.L.), the Strategic Priority Research Program of the Chinese Academy of Sciences (XDB36000000 to G.N.), CAS Project for Young Scientists in Basic Research (No. YSBR-036 to S.L.), the Key Area R&D Program of Guangdong Province (2020B0101020004 to S.L.), the National Basic Research Plan of China (2018YFA0208900 to G.N.), and the National Natural Science Foundation of China (31730032 to G.N., 31820103004 to G.N.).
Publisher Copyright:
© 2023, Springer Nature Limited.
PY - 2024/1
Y1 - 2024/1
N2 - Systemic antiplatelet treatment represents a promising option to improve the therapeutic outcomes and therapeutic efficacy of chemotherapy and immunotherapy due to the critical contribution of platelets to tumour progression. However, until recently, targeting platelets as a cancer therapeutic has been hampered by the elevated risk of haemorrhagic and thrombocytopenic (low platelet count) complications owing to the lack of specificity for tumour-associated platelets. Recent work has advanced our understanding of the molecular mechanisms responsible for the contribution of platelets to tumour progression and metastasis. This has led to the identification of the biological changes in platelets in the presence of tumours, the complex interactions between platelets and tumour cells during tumour progression, and the effects of platelets on antitumour therapeutic response. In this Review, we present a detailed picture of the dynamic roles of platelets in tumour development and progression as well as their use in diagnosis, prognosis and monitoring response to therapy. We also provide our view on how to overcome challenges faced by the development of precise antiplatelet strategies for safe and efficient clinical cancer therapy.
AB - Systemic antiplatelet treatment represents a promising option to improve the therapeutic outcomes and therapeutic efficacy of chemotherapy and immunotherapy due to the critical contribution of platelets to tumour progression. However, until recently, targeting platelets as a cancer therapeutic has been hampered by the elevated risk of haemorrhagic and thrombocytopenic (low platelet count) complications owing to the lack of specificity for tumour-associated platelets. Recent work has advanced our understanding of the molecular mechanisms responsible for the contribution of platelets to tumour progression and metastasis. This has led to the identification of the biological changes in platelets in the presence of tumours, the complex interactions between platelets and tumour cells during tumour progression, and the effects of platelets on antitumour therapeutic response. In this Review, we present a detailed picture of the dynamic roles of platelets in tumour development and progression as well as their use in diagnosis, prognosis and monitoring response to therapy. We also provide our view on how to overcome challenges faced by the development of precise antiplatelet strategies for safe and efficient clinical cancer therapy.
UR - http://www.scopus.com/inward/record.url?scp=85178225207&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85178225207&partnerID=8YFLogxK
U2 - 10.1038/s41568-023-00639-6
DO - 10.1038/s41568-023-00639-6
M3 - Review article
C2 - 38040850
AN - SCOPUS:85178225207
SN - 1474-175X
VL - 24
SP - 72
EP - 87
JO - Nature Reviews Cancer
JF - Nature Reviews Cancer
IS - 1
ER -